Company news

Neuren Pharmaceuticals Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Commentary on potential benefit to Neuren of RPD designation

March 3, 2020

Rare Pediatric Disease designation received from FDA

March 3, 2020

Appendix 4E and 2019 full year accounts

February 25, 2020

Update on trofinetide Phase 3 trial in Rett syndrome

February 19, 2020

2019 year-end update and 2020 outlook

December 11, 2019

Patent to 2034 granted in Europe for Neurens NNZ-2591

December 2, 2019

Phase 3 trial of trofinetide in Rett syndrome commences

October 30, 2019

FDA Grants Orphan Drug Designation for Neuren's NNZ-2591 to Treat Angelman, Phelan-McDermid and Pitt Hopkins Syndromes

October 17, 2019

FDA grants Orphan for both Phelan-McDermid and Pitt Hopkins

October 15, 2019

FDA grants Orphan Drug Designation for NNZ-2591 in Angelman

October 11, 2019

Neuren approaching key milestones in Q4 2019

September 20, 2019

NNZ-2591 positive effects in Pitt Hopkins syndrome model

May 17, 2019

NNZ-2591 positive effects in Angelman syndrome model

May 16, 2019

Update on development plan for NNZ-2591

April 26, 2019

Neurens Rett syndrome Phase 2 trial published in Neurology

March 27, 2019

Preliminary Final Report and statutory accounts

February 27, 2019

NNZ-2591 positive effects in Phelan-McDermid syndrome model

February 17, 2019

Trofinetide ex-North America exclusive negotiation period

October 25, 2018

Neuren and Lanstead agree to pause settlements for 120 days

August 29, 2018

Neuren receives initial payment of US$10 million from ACADIA

August 22, 2018

Neuren and ACADIA announce agreement for North America

August 6, 2018

Announcement of buy-back - Appendix 3C

May 30, 2018

Neuren announces investment and exclusive negotiation period

May 20, 2018

First patent in Japan granted for Neurens trofinetide

April 29, 2018

Disclosure under Listing Rule 4.3D

March 29, 2018

S&P DJ Indices Announces March Quarterly Rebalance

March 8, 2018

Preliminary Final Report

February 28, 2018

Neuren announces new US patent to be granted for NNZ-2591

December 5, 2017

Consolidation/Split - NEU

November 16, 2017

Neuren FDA meeting confirms Phase 3 plan for Rett syndrome

October 12, 2017

Presentations and publication for Rett syndrome trials

October 4, 2017

Change of Director's Interest Notice

August 29, 2017

Notice under section 708A(5)(e) of the Corporations Act

August 29, 2017

Results of Meeting

August 28, 2017

Neuren Pharmaceuticals reports 2017 half-year results

August 24, 2017

Notice of special meeting of shareholders

August 14, 2017

Neuren granted Type B Meeting with FDA for Rett syndrome

July 20, 2017

Neuren Pharmaceuticals granted Type B Meeting with FDA for Rett syndrome

July 19, 2017

Appendix 3B

July 18, 2017

Neuren secures funding for key activities for Rett syndrome

June 29, 2017

Response to ASX Price Query

June 28, 2017

Response to ASX Price Query

June 27, 2017

Trading Halt

June 27, 2017

Investor presentation, 2 June 2017

June 1, 2017

Neuren announces grant of two new patents to 2032

May 31, 2017

Notice of Annual General Meeting/Proxy Form

May 29, 2017

Response to Appendix 4C Query

May 8, 2017

Neuren receives $1 million R&D Tax Incentive

April 4, 2017

Trofinetide significant clinical benefit in Rett syndrome

March 21, 2017

Neuren completes Phase 2 trial in pediatric Rett syndrome

January 29, 2017

← Newer news releases · Older news releases →

Decks

The 5 newest of 91 decks. Every deck is listed under its year.